Examination of the Impact of CalmiGo's Stress Management Device on Vascular Heath and Cardiovascular Disease Risk.

Myocardial Infarction Clinical Trial

— CalmiGo  

Official title:

Examination of the Impact of CalmiGo's Stress Management Device on Vascular Health and Cardiovascular Disease Risk , and Markers of Mental Stress in Patients Following a Myocardial Infarction Participating in Clinically Indicated Cardiac Rehabilitation

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04521699
• Other study ID #: 20-005047
• Status: Recruiting
• Phase: N/A
• Start date: January 13, 2022
• Est. completion date: January 2025

Study information

• Verified date: December 2023
• Source: Mayo Clinic
• Contact: Amanda Priebe
• Phone: 507-422-6932
• Email: Priebe.Amanda[@]mayo.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary purpose of this study is to determine if there are significant differences with respect to baseline between those randomized to CGo and standard-of-care versus standard-of-care alone after completing 12-weeks of therapy in terms of peripheral endothelial function measured by EndoPAT.

Description:

100 patients who have recently had an acute Myocardial Infarction ( heart attack) and are under going clinically indicated cardiac rehabilitation will undergo baseline testing including EndoPAT testing, mental stress testing, blood tests for cardiovascular disease biomarkers , physical assessments & survey questionnaires. Patients then will be randomized to either CalmioGO stress management device + standard of care treatment or just standard of care treatment. Those randomized to CalmiGO stress management device treatment will be instructed to use the hand device much like an inhaler once a day for 12 weeks. After 12 weeks of rehabilitation both groups will return for reassessment of baseline tests.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100
• Est. completion date: January 2025
• Est. primary completion date: January 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• 18 years of age or older

• Ability to use the CamliGo device for 12-weeks

• Willingness to complete study questionnaires, blood tests,& EndoPat testing at the beginning and end of study

• Patients who have had a recent MI who will be undergoing clinically indicated Cardiac Rehabilitation

• Patients who have had a coronary or structural intervention performed in the cardiac catheterization laboratory within the last month, including: coronary stenting; coronary balloon angioplasty; transcatheter aortic valve replacement; mitral valve interventions; patent foramen ovale closures; alcohol septal ablation; paravalvular leak closure.

• Patients being seen in the Chest Pain Clinic for Atypical chest pain

Exclusion Criteria:

• Cognitively impaired patients

• Patient with Bipolar disorder, psychosis or delusional disorder

• History of substance abuse or dependence

• History of suicidality

• Unstable cardiovascular or pulmonary disease

• History of seizures

• Latex allergy

Related Conditions & MeSH terms

• Cardiovascular Diseases
• Infarction
• Myocardial Infarction

Intervention

Device:
• CalmioGO Stress management device
CalmiGo device is a device of similar size to an inhaler that uses guided breathing, and grounding techniques to regulate breathing to bring users a sense of calm and relaxation.

Locations

Country	Name	City	State
United States	Mayo Clinic in Rochester	Rochester	Minnesota

Sponsors (2)

Lead Sponsor	Collaborator
Mayo Clinic	CalmiGO

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Peripheral endothelial function	Measurements made at baseline will be significantly different between those randomized to CalmioGo + standard of care to those receiving only standard of care treatment	16 weeks
Secondary	Physical assessments, cardiovascular disease biomarker blood tests as well resilience, joy, gratitude, mindfulness, health behavior , overall quality of life & perceived stress.	Measurements made at baseline will be significantly different between those randomized to CalmiGo + standard of care then those to just standard of care.	16 weeks

External Links

•   Mayo Clinic Clinical Trials